InnoCan Pharma Corporation (CSE:INNO)

InnoCan Pharma Statistics

Total Valuation

InnoCan Pharma has a market cap or net worth of CAD 33.74 million. The enterprise value is 29.61 million.

Market Cap	33.74M
Enterprise Value	29.61M

Important Dates

The next estimated earnings date is Tuesday, March 31, 2026.

Earnings Date	Mar 31, 2026
Ex-Dividend Date	n/a

Share Statistics

InnoCan Pharma has 4.50 million shares outstanding. The number of shares has increased by 5.42% in one year.

Current Share Class	4.50M
Shares Outstanding	4.50M
Shares Change (YoY)	+5.42%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	3.41%
Owned by Institutions (%)	n/a
Float	3.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.90
PB Ratio	3.65
P/TBV Ratio	6.29
P/FCF Ratio	43.41
P/OCF Ratio	42.35
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.57
EV / Sales	0.79
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	38.09

Financial Position

The company has a current ratio of 3.72, with a Debt / Equity ratio of 0.23.

Current Ratio	3.72
Quick Ratio	2.72
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	2.73
Interest Coverage	-312.98

Financial Efficiency

Return on equity (ROE) is -33.07% and return on invested capital (ROIC) is -10.37%.

Return on Equity (ROE)	-33.07%
Return on Assets (ROA)	-7.56%
Return on Invested Capital (ROIC)	-10.37%
Return on Capital Employed (ROCE)	-15.35%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	2.61
Inventory Turnover	1.06

Taxes

In the past 12 months, InnoCan Pharma has paid 1.03 million in taxes.

Income Tax	1.03M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.05% in the last 52 weeks. The beta is -0.04, so InnoCan Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.04
52-Week Price Change	-45.05%
50-Day Moving Average	14.99
200-Day Moving Average	13.27
Relative Strength Index (RSI)	24.54
Average Volume (20 Days)	1,145

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCan Pharma had revenue of CAD 37.64 million and -4.50 million in losses. Loss per share was -1.01.

Revenue	37.64M
Gross Profit	33.30M
Operating Income	-1.74M
Pretax Income	-2.10M
Net Income	-4.50M
EBITDA	-1.69M
EBIT	-1.74M
Loss Per Share	-1.01

Balance Sheet

The company has 10.13 million in cash and 2.12 million in debt, giving a net cash position of 8.00 million or 1.78 per share.

Cash & Cash Equivalents	10.13M
Total Debt	2.12M
Net Cash	8.00M
Net Cash Per Share	1.78
Equity (Book Value)	9.24M
Book Value Per Share	1.19
Working Capital	11.23M

Cash Flow

In the last 12 months, operating cash flow was 796,733 and capital expenditures -19,500, giving a free cash flow of 777,233.

Operating Cash Flow	796,733
Capital Expenditures	-19,500
Free Cash Flow	777,233
FCF Per Share	0.17

Margins

Gross margin is 88.47%, with operating and profit margins of -4.63% and -11.96%.

Gross Margin	88.47%
Operating Margin	-4.63%
Pretax Margin	-5.57%
Profit Margin	-11.96%
EBITDA Margin	-4.50%
EBIT Margin	-4.63%
FCF Margin	2.06%

Dividends & Yields

InnoCan Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.42%
Shareholder Yield	-5.42%
Earnings Yield	-13.35%
FCF Yield	2.30%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 5, 2025. It was a reverse split with a ratio of 0.015384615.

Last Split Date	Sep 5, 2025
Split Type	Reverse
Split Ratio	0.015384615

Scores

InnoCan Pharma has an Altman Z-Score of 3.83 and a Piotroski F-Score of 3.

Altman Z-Score	3.83
Piotroski F-Score	3